Evaluating a New Cardiac Rehabilitation Approach for Adults With Ischemic Heart Disease A Prospective, Randomized Controlled Study Comparing New and Traditional Therapies

What this Trial Is About

Researchers are evaluating a new cardiac rehabilitation therapy for patients with ischemic heart disease, including coronary heart disease and heart failure. This prospective, randomized, controlled study aims to compare the effectiveness and home rehabilitation compliance of the new therapy against traditional cardiac rehabilitation. The study follows a PICOST design and focuses on improving myocardial perfusion and other cardiovascular health measures. Participants receive either conventional drug therapy combined with the new cardiac rehabilitation treatment, which includes early respiratory rehabilitation, phase I rehabilitation, exercise therapy, external counterpulsation, and extracorporeal shock wave therapy, or conventional drug therapy combined with traditional cardiac rehabilitation based on national and international guidelines. Treatment duration varies between 1 week and 3 months depending on patient needs. During the study, participants will undergo assessments such as DSPECT imaging to measure changes in myocardial infarct area over 6 months. Additional evaluations include blood biochemical tests, myocardial necrosis markers, cardiopulmonary exercise testing, and monitoring of major adverse cardiovascular events. Researchers will also track patient and family adherence to rehabilitation treatments to evaluate long-term outcomes and safety.

A New Cardiac Rehabilitation Treatment in the Application of Ischemic Heart Disease